Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumorspecific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3 -a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42-51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2 0 -deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG that is frequently inactivated epigenetically in multiple carcinomas.
Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumorspecific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3 -a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42-51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2 0 -deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG
Introduction
Cell migration and calcium-dependent, cadherinmediated homophilic cell-cell interactions are critical events during development, morphogenesis and woundhealing. The mammalian cadherin superfamily is characterized by the presence of a unique domain called the cadherin motif or ectodomain (EC domain) (Gumbiner and Yamada, 1995; Shapiro et al., 1995) . This family includes classic cadherins, protocadherins, desmogleins, desmocollins, cadherin-related neuronal receptors (CNRs), FATs, seven-pass transmembrane cadherins and Ret tyrosine kinase (Yagi and Takeichi, 2000; Angst et al., 2001) . The EC domains are randomly repeated in the extracellular segment of all cadherin members, but the number of repeats varies among these molecules (Yagi and Takeichi, 2000) . Although the presence of EC domains is a marker for this superfamily, the amino-acid sequences of other domains of these proteins, particularly the cytoplasmic domain, vary significantly (Angst et al., 2001) . Protocadherin is a recently discovered, major subfamily of the cadherin superfamily, although slightly different in their protein structures (Wu and Maniatis, 2000; Frank and Kemler, 2002) . Protocadherins are a heterogenous group of proteins with multi functions. They contain six extracellular cadherin domains, a transmembrane domain and a different cytoplasmic tail from the classical cadherins (Frank and Kemler, 2002) . Protocadherins also exhibit cell-to-cell adhesion activities, but the mechanism is thought to be distinct from that of classical cadherins (Suzuki, 2000; Frank and Kemler, 2002) . Protocadherins are believed to possess other important functions as well, such as signal transduction and growth control, although the exact functions of most protocadherins have not been well elucidated.
The expression of cadherins is tightly regulated during development, and each tissue or cell type shows a characteristic pattern of cadherin expression (Angst et al., 2001 ). Downregulation of cadherins or their functional alterations have been frequently observed in human malignancies, which promotes tumor cell invasion and metastasis (Berx et al., 1995; Perl et al., 1998) , suggesting that at least some cadherins can act as tumor suppressor genes (TSG). Mutations of E-cadherin (CDH1) have been reported in familial and sporadic gastric cancers and other tumors (Risinger et al., 1994; Berx et al., 1995; Guilford et al., 1998) . CDH13 also has truncating mutations in tumors which lead to the deletion of transmembrane and cytoplasmic regions and disruption of its tumor suppression functions (Lee, 1996) . Downregulation of CDH1, H-cadherin/Cadherin-13 (CDH13) and recently CDH4 by promoter methylation has been observed in many epithelial tumors (Graff et al., 1995; Yoshiura et al., 1995; Toyooka et al., 2001; Miotto et al., 2004) .
As for protocadherins, the Drosophila protocadherin fat, which is the largest protocadherin, has been reported as a tumor suppressor. Recessive lethal mutations in the fat locus in Drosophila caused hyperplastic, tumor-like overgrowth of imaginal discs, and defects in differentiation and morphogenesis (Mahoney et al., 1991) . Although its mouse homolog (mfat) behaves differently not like a TSG since it is frequently expressed in highly proliferative cells, its human FAT was recently found to be frequently hypermethylated in tumors although no functional study was performed (Paz et al., 2003) . The protocadherin LKC is associated with contact inhibition of cell proliferation, and has been suggested as a candidate TSG for colon and liver cancer (Okazaki et al., 2002) . Mutations in protocadherin 15 as well as CDH23 have also been implicated in Usher syndrome (Bolz et al., 2001; Di et al., 2001; Siemens et al., 2002) , as recently demonstrated in a zebrafish model Sollner et al., 2004) .
Epigenetic alterations resulting in the loss of TSG functions are frequently involved in tumor development and progression (Knudson, 2001; Jones and Baylin, 2002) . Aberrant methylation of TSG-associated CpG islands (CGI) is a characteristic epigenetic feature of tumor genomic DNA. There are ample examples of well-recognized TSGs showing promoter CGI methylation in various tumors, such as p16
INK4a , hMLH1, VHL, BRCA1, RASSF1A, HIC1, etc (Jones and Baylin, 2002) . Based on the epigenetic theory that tumor-specific promoter methylation is a marker for TSGs, we combined methylation-sensitive representational difference analysis (MS-RDA) (Ushijima et al., 1997) with pharmacologic demethylation using 5-aza-2 0 -deoxycytidine (Aza) to screen for aberrantly methylated genes in nasopharyngeal carcinoma (NPC), which is a highly prevalent tumor in our locality of Southern China and Southeast Asia. We identified protocadherin 10 (PCDH10/OL-PCDH/KIAA1400), a recently discovered protocadherin with widespread expression (Wolverton and Lalande, 2001) , as a target gene for epigenetic inactivation in NPC, as well as in several other common carcinomas. We further demonstrated that exogenous expression of PCDH10 strongly suppressed the tumor cell growth, migration, invasion and colony formation of several carcinomas, indicating that PCDH10 can function as a broad TSG in multiple carcinomas.
Results
Epigenetic identification of the PCDH10 CGI as a hypermethylated sequence in NPC DNA fragments hypermethylated in the NPC cell line CNE-1 that became demethylated after Aza treatment were identified using the subtractive MS-RDA (Ushijima et al., 1997) and further analysed by bioinformatics (Ying and Tao, manuscript in preparation) . Among the 31 DNA fragments identified, one sequence spans the proximal promoter and exon 1 of the PCDH10 gene, which is a recently discovered protocadherin located at 4q28.3 (Wolverton and Lalande, 2001) . CpG site analysis (Qiu et al., 2004) revealed that the PCDH10 promoter is a typical CGI (Figure 1a ). PCDH10 is located outside the hemizygous deletion at 4q28.3 identified by array-CGH in NPC Genomewide identification of deletions using array-CGH (Hurst et al., 2004) could also identify candidate TSGs with genetic inactivation in tumors (Knudson, 2001 ). We performed 1-Mb array-CGH to identify DNA copy number aberrations in a few tumor cell lines including NPC. Among a series of deletions and amplifications detected in NPC (Seng et al., unpublished) , 4q28.3 was found to have a hemizygous deletion (around 1.5 Mb) in 9/11 NPC cell lines. Although this is the previously identified locus for PCDH10, PCDH10 itself was actually around 1.5-Mb away from the deletion region and not deleted in these cell lines ( Figure 1b) . As recognized recently, candidate TSGs are more frequently inactivated through epigenetic inactivation (promoter methylation), or a combination of genetic (mutations of one allele) and epigenetic (methylation of another allele) inactivations, than biallelic genetic inactivation alone (Jones and Baylin, 2002) . Since the PCDH10 promoter is a CGI which is generally unmethylated in normal cells but may become methylated in tumors, PCDH10 was further examined for its epigenetic inactivation in tumors.
Frequent promoter methylation of PCDH10 in NPC cell lines but not normal nasopharyngeal epithelial cells We first determined the methylation status of PCDH10 in NPC cell lines. The location of the PCDH10 promoter has been previously mapped by 5 0 -RACE (Wolverton and Lalande, 2001) . Based on its promoter sequence, we designed methylation-specific PCR (MSP) primers to analyse its methylation status in NPC cell lines. In CNE-1, which was used for our initial subtraction, the promoter CGI of PCDH10 was completely methylated but became half demethylated after Aza treatment, as confirmed by both MSP and bisulfite genomic sequencing (BGS) analyses (Figures 2a  and 5c ). Analysis of a panel of NPC cell lines showed that PCDH10 methylation occurred in all, while only unmethylated alleles were detected in the immortalized normal nasopharyngeal epithelial cell line -NP69 (Figure 2b ). Moreover, PCDH10 expression was completely silenced in all of the NPC cell lines (except for very weak expression in C666-1), compared to the strong expression in NP69 (Figure 2b ). To examine PCDH10 methylation in more detail, we analysed four NPC cell lines and NP69 using the highresolution BGS analysis. The results confirmed our MSP analysis. Very few methylated CpG sites was detected in NP69, which strongly expresses PCDH10. In contrast, a high density of methylated CpG sites were detected in all NPC cell lines without PCDH10 expression (Figure 2c ). No unmethylated allele was detected in these silenced cell lines, indicating a biallelic inactivation by methylation. Thus, a strong correlation was observed between transcriptional silencing of PCDH10 and its promoter methylation.
Frequent silencing of PCDH10 by promoter methylation in multiple carcinoma cell lines Previously, PCDH10 has been shown to be strongly expressed in the brain, as well as heart, kidney, lung and trachea (Wolverton and Lalande, 2001) . We have further examined its expression in a panel of 30 human normal adult and fetal tissues by semiquantitative reverse transcription (RT)-PCR. Our results showed that PCDH10 was expressed in all normal tissues, though at different expression levels, including the respiratory system tissues (larynx, trachea and lung), which are closely related to the corresponding normal . The expression levels in normal fetal tissues were slightly stronger than adult tissues, while weak expression was detected in some tissues such as adult liver, bone marrow and spleen, as reported previously (Wolverton and Lalande, 2001 ). The expression pattern of PCDH10 is similar to the largest protocadherin -human FAT, which was recently shown to be methylated in tumors (Dunne et al., 1995; Paz et al., 2003) . As PCDH10 was widely expressed in normal tissues, we further examined its expression and methylation in a large collection of carcinoma cell lines to determine whether there is a wide-spread epigenetic inactivation of this gene. By semiquantitative RT-PCR, we found that PCDH10 expression was reduced or silenced in 81% (13/16) esophageal, 75% (3/4) breast, 75% (3/4) cervical, 25% (2/8) heptacellular, 67% (2/3) lung and 100% (2/2) colorectal carcinoma cell lines and a few other cell lines ( Figure 3b and Table 1 ). PCDH10 methylation status was also analysed by MSP in these cell lines. We found that cell lines with reduced or silenced expression had methylated promoters. In contrast, virtually no methylation was found in the immortalized normal epithelial cell lines, which expressed PCDH10 (Figure 3c ). Detailed BGS analysis confirmed the MSP results ( Figure 3d ). The promoter methylation in most cell lines was also biallelic. Thus, PCDH10 hypermethylation strongly correlates with its transcriptional silencing in multiple carcinoma cell lines. We did not detect any homozygous deletion of this gene in tumor cell lines.
Frequent hypermethylation of PCDH10 in multiple primary tumors
We further investigated the presence of PCDH10 methylation in a large collection of primary carcinomas, with their corresponding normal epithelial tissues as controls ( Figure 4 and Table 1 ). PCDH10 methylation was detected in 82% (31/38) of NPC, 51% (18/35) of esophageal, 45% (9/20) of breast, 42% (8/19) of gastric and 42% (5/12) of hepatocellular carcinomas. Aberrant methylation was also detected in 6% (2/35) surgical marginal esophageal tissues from patients with esophageal carcinoma, which could be due to the appearance of premalignant lesions, or the presence of small number of tumors cells disseminated into the non-tumorous region. None of the nine normal epithelial tissues (three nasopharynx and six breast) and six normal hepatocellular tissues from hepatocellular carcinoma patients had promoter methylation. These results demonstrate that hypermethylation of the PCDH10 promoter is a common event in the tumorigenesis of multiple carcinomas and is tumor-specific.
Pharmacologic and genetic demethylation activates PCDH10 expression Robust induction was observed in methylated NPC cell lines after treatment with the demethylating agent Aza (Figure 5a ). We also found that PCDH10 could be activated in the colorectal cancer cell line HCT116 which is completely methylated for this gene, by genetic demethylation through double knockout (KO) of both DNMT1 and DNMT3B (DKO cell line), but not single KO of DNMT1 or DNMT3B alone (1KO or 3BKO cell PCDH10 as a broad tumor suppressor methylated in carcinomas J Ying et al line) (Figure 5b ). Concomitantly, unmethylated PCDH10 alleles were strongly detected in Aza-treated and DKO cells, but not in DNMT1 or DNMT3B single KO cells, indicating that methylation directly mediates the silencing of PCDH10. Further high-resolution methylation analysis by BGS confirmed the demethylation of PCDH10 alleles (Figure 5c ). These results also suggest that the maintenance of PCDH10 methylation is mediated by DNMT1 and DNMT3B together, like other bona-fide TSGs we and others have examined (Tao et al., unpublished; Paz et al., 2003) .
PCDH10 inhibits tumor cell proliferation, migration and clonogenicity The frequent silencing of PCDH10 by methylation in multiple carcinoma cell lines and primary carcinomas but not normal epithelial tissues suggests that PCDH10 is likely a functional tumor suppressor. To test this, we examined the physiologic effect of PCDH10 on cell proliferation, migration, invasion and clonogenicity of several carcinoma cell lines. We transfected a PCDH10-expression vector into cell lines that had complete methylation and silencing of PCDH10 (CNE-1, HCT116 and the esophageal carcinoma cell line EC109). The colony formation efficiencies of each transfected cell line were evaluated by monolayer and soft-agar culture. Ectopic expression of PCDH10 dramatically reduced the colony formation efficiencies of these cell lines in monolayer culture (down to 24-33% of controls) (Figure 6a ) and soft-agar assays (Figure 6b ), suggesting that PCDH10 does function as a TSG in these tumor cells.
Cell proliferation assay was also performed for stably transfected CNE-1 and EC109 cells. Cells stably transfected with pcDNA3.1( þ )PCDH10 grew significantly slower than the vector-transfected cells (Po0.001) (Figure 7b ), indicating that PCDH10 also strongly inhibits tumor cell proliferation. The expression levels of PCDH10 in these stably transfected clones were similar to those observed in unmethylated normal cell lines, except for being even lower in CNE-1/PCDH10c2 (Figure 7a) . To eliminate the possibility that the inhibitory effect was due to the overexpression of PCDH10, the stable clone CNE-1/PCDH10-c2 with lower expression of PCDH10 was compared with CNE-1/PCDH10-c1, a clone with normal level of PCDH10 PCDH10 as a broad tumor suppressor methylated in carcinomas J Ying et al (Figure 7a ), but no significant difference in cell growth inhibition was observed. Next, the effect of PCDH10 on NPC (CNE-1) and esophageal carcinoma (EC109) cell motility was assessed by scratch wound assay. PCDH10-expressing cells spread along the wound edges significantly slower than vector-transfected cells (Figure 7c ), indicating that PCDH10 also inhibits tumor cell migration.
Furthermore, a matrigel assay was performed to examine the invasive potential of EC109 cells transfected with PCDH10. As shown in Figure 7d , the number of cells that migrated through the Matrigel membrane into the lower chamber was significantly lower in the two stable clones of PCDH10-transfected EC109 cells than in control cells (44% for PCDH10c1 and 21% for PCDH10c2, respectively, relative to the control), suggesting that PCDH10 also inhibits the invasive potential of carcinoma cells.
Discussion
In this report, we used a novel approach of combining MS-RDA with pharmacologic demethylation to identify hypermethylation-silenced genes in tumors. These aberrantly hypermethylated genes are likely candidate TSGs. We identified PCDH10 as such a candidate gene, frequently silenced by methylation in a tumor-specific manner. We further showed that ectopic expression of PCDH10 in silenced carcinoma cell lines dramatically inhibits not only tumor cell colony formation, migration and invasion, but also their proliferation, and that even a low level of PCDH10 expression could achieve this inhibitory effect. These results suggest that PCDH10 is important for the suppression of carcinoma cells and its absence may permit tumor growth and expansion. Thus, PCDH10 can act as a functional TSG in multiple carcinoma cells, in addition to its reported classical role in nervous system development.
Epigenetic gene silencing is associated with the onset and progression of various cancers, and it is now well accepted that epigenetic alterations even precede genetic changes during tumorigenesis (Jones and Baylin, 2002) . Epigenetic silencing can occur via promoter methylation and/or modification of histone tails in the chromatin. These two epigenetic events are closely linked and affect each other through the interaction of DNMT with the HDAC complex at methylated CpG sites (Robertson et al., 2000; Rountree et al., 2000) . Pharmacologic (such as Aza treatment) or genetic demethylation (through double KO of DNMT1 and DNMT3B) results in the hypomethylation of genomic DNA, thus restoring the expression of methylation-silenced genes (Rhee et al., . Pharmacologic demethylation has been explored as a cancer therapeutic strategy through reactivating TSG functions and inducing tumor cell apoptosis or silenced viral immunodominant proteins (Chan et al., 2004; Szyf et al., 2004) . The same strategy has also been used successfully to identify aberrantly methylated candidate TSGs (Suzuki et al., 2002) . While MS-RDA has been used to identify methylated sequences in several tumors (Kaneda et al., 2003) , the combination of pharmacologic demethylation with MS-RDA provides us with a more specific way to identify aberrant epigenetic alterations across the whole tumor cell genome, and to search for candidate TSGs that are important in tumorigenesis.
Through this approach, we cloned and identified a few novel methylated genes with typical CGI and aberrant methylation in tumors, such as PCDH10 -a protocadherin. As protocadherins were just discovered recently (Wu and Maniatis, 2000) , the functions of most protocadherins were poorly defined, especially with respect to tumorigenesis. Some protocadherins including PCDH10 are involved in the development of the central nervous system (Wolverton and Lalande, 2001; Nakao et al., 2005) . Although the expression of some protocadherins (like PCDH8) is quite tissue-specific (mainly in brain), the expression of most protocadherins (such as PCDH15, FAT and PCDH10 in this study) is broad in multiple tissues. Different from cadherins, protocadherins are not just simple cell adhesion proteins involved in homophilic interactions (Suzuki, 2000; Frank and Kemler, 2002) . Heterophilic interactions with other molecules may be more important for their physiologic functions, such as the involvement in signal transduction. For example, protocadherin LKC interacts with the PDZ domain-containing protein kinase hMAST205 (Okazaki et al., 2002) . The Drosophila tumor suppressor protocadherin fat controls planar polarity through physical interactions with a transcriptional corepressor Atrophin (Fanto et al., 2003) . So far, three classical cadherins (CDH1, CDH13, CDH4) have been defined as functional TSGs with frequent epigenetic silencing in multiple tumors (Graff et al., 1995; Yoshiura et al., 1995; Toyooka et al., 2001; Miotto et al., 2004) . Only one protocadherin, protocadherin LKC, was reported to inhibit tumor cell proliferation as a candidate TSG (Okazaki et al., 2002) . Our study appears to be the first report that a protocadherin gene can function as a broad TSG, meanwhile being frequently inactivated epigeneti- PCDH10 as a broad tumor suppressor methylated in carcinomas J Ying et al cally in multiple carcinomas, including NPC, esophageal, hepatocellular, breast, cervical, lung and colorectal carcinomas. Our further studies on other tumors including various lymphomas (Ying and Tao, unpublished) indicate that epigenetic inactivation of PCDH10 is common in many malignancies. We did not detect any homozygous deletion of PCDH10 in tumor cell lines. More work is needed to assess whether other genetic inactivation, including point mutations, is involved in tumorigenesis, as reported for CDH1 and CDH13. The current data support the notion that PCDH10 is a newage (Class II) TSG being inactivated by epigenetic alterations (Knudson, 2001) . The molecular mechanism of how PCDH10 inhibits tumor cell growth is unclear. The mouse Pcdh10 only weakly mediates cell aggregation (Hirano et al., 1999) , indicating that cell-cell adhesion may not be its major function. PCDH10 is a typical protocadherin with a cytoplasmic motif, CM-2, homologous to a laminin-type EGF-like (LE) domain (Wolverton and Lalande, 2001 ). CM-2 is also similar to the C 2 HC-type zinc-finger or zinc knuckle finger motif (Matthews et al., 2000) . Since some zinc fingers also mediate protein-protein interaction, CM-2 could represent a functional domain of PCDH10 interacting with other cellular proteins. One major mechanism for cadherins in tumor suppression is through the Wnt/b-catenin/Tcf signaling pathway (Angst et al., 2001) , an important gatekeeper of tumorigenesis (Berx et al., 1995; Perl et al., 1998) . However, protocadherins including PCDH10 do not bind to b-catenin (Frank and Kemler, 2002) , so whether they can also interfere with the Wnt signaling pathway is unclear.
Our preliminary work also indicates that other protocadherins may function as putative TSGs too (Ying and Tao, unpublished) . The upregulation of another protocadherin -PCDH8 (13q14.3) in colon cancer cells after pharmacologic demethylation with Aza indicates that it is also aberrantly silenced by methylation in tumors (Suzuki et al., 2002) . Meanwhile, we found that PCDH7 (4p15) and PCDH9 (13q14.3-q21.1) were upregulated in tumor cells after demethylation, indicating that they could also be candidate genes aberrantly silenced by methylation in tumors (Tao et al, unpublished) .
In this study, we also analysed four normal epithelial cell lines, immortalized by SV40 T-antigen (NP69, NE3) (Tsao et al., 2002) , or a hybrid of adenovirus 12 and SV40 virus (RHEK-1) or HPV-E6/E7 (NE1). These cell lines are good premalignant model systems for studying the mechanism of multi-step pathogenesis of carcinomas. Normal PCDH10 expression is nevertheless maintained in these cell lines, distinct from its frequent silencing in most carcinoma cell lines, and in line with their property of anchorage-dependent growth. Therefore, loss of PCDH10 functions is probably a mid-stage event during carcinogenesis and related to the conversion to anchorage-independent growth.
In summary, we found that PCDH10 is frequently methylated in NPC cell lines. Although widely expressed in normal tissues, PCDH10 is frequently silenced by methylation in a variety of carcinomas including NPC, which could be activated by pharmacological or genetic demethylation. We further demonstrated that PCDH10 can act as a functional TSG in multiple carcinoma cells. During the final preparation of this manuscript, Yu (2005) reported the identification of mouse Pcdh10 CGI as a methylated sequence in a mouse leukemia model. The methylation of another protocadherin -PCDH-gamma-A11 -in astrocytomas was also recently reported (Waha et al., 2005) . Although both reports did not provide any further epigenetic or functional analysis to show these protocadherins as candidate TSGs, their results are complementary to ours and suggest that epigenetic inactivation of protocadherins in tumors could be widespread indeed.
Materials and methods

Cell lines and tumor samples
A total of 55 carcinoma cell lines were studied, including nasopharyngeal -NPC (C666-1, CNE-1, CNE-2, HK1, NPC-BM1, HNE1, HNE2, HNE3, HONE-1, 5-8F, 6-10B, HKM1), esophageal (EC1, EC18, EC109, HKESC1, HKESC2, SLMT1, KYSE30, KYSE70, KYSE140, KYSE150, KYSE180, KYSE270, KYSE410, KYSE450, KYSE510 and KYSE520), hepatocellular (HepG2, huH1, huH4, huH6, huH7, Hep3B, SNU398, SNU475), colorectal (HCT116, HT-29, HCT15, SW48 and LoVo), cervical (HeLa, CaSki, C33A, SiHa), lung (A549, H-1299, H2126, H1395, H292), breast (MCF-7, T47D, ZR-75-1, MB231) and gastric carcinomas (Kato III) (Ying et al., 2005) . Four immortalized normal epithelial cell lines (NP69, NE1, NE3, RHEK-1) (Hukku et al., 1997; Tsao et al., 2002) (Rhee et al., 2002) . DNA and RNA samples from various primary carcinomas have been described previously (Tao et al., 1998 (Tao et al., , 1999 Qiu et al., 2004; Ying et al., 2004 Ying et al., , 2005 . Cell lines were treated with Aza (Sigma, St Louis, MO, USA) as described previously (Qiu et al., 2004) . Methylation-sensitive representational difference analysis MS-RDA was performed as described (Ushijima et al., 1997; Ying et al., 2005) . Briefly, we used the genomic DNA of the NPC cell line CNE-1 (the Driver) and CNE-1 treated with 50 mM Aza (the Tester), and performed two cycles of competitive hybridization. PCR products from the second hybridization were cloned, sequenced and analysed using the BLASTN algorithm (NCBI).
Array-CGH
Whole-genome arrays of 1-Mb resolution with 3040 BAC/ PAC clones were provided by the Sanger Institute, UK (http:// www.sanger.ac.uk/Projects/Microarrays/) (Hurst et al., 2004) . Clones details are listed in Ensembl (http://www.ensembl.org/ Homo_sapiens/index.html). Array-CGH was performed with slight modification (Fiegler et al., 2003; Hurst et al., 2004) . Briefly, sample DNA (600 ng) was labeled with Cy5-dCTP (Amersham Pharmacia), whereas reference DNA of normal PBMCs from healthy Chinese donors was labeled with Cy3-dCTP using the BioPrime Array CGH Genomic Labeling System (Invitrogen, Carlsbad, CA, USA). Unincorporated nucleotides were removed using Purification Module supplied in the labeling system. Labeled sample and normal DNA (50 ml each) were mixed and ethanol precipitated together with 67.5 ml of human Cot1 DNA (Invitrogen), and resuspended in 30 ml of hybridization buffer, denatured and prehybridized in a humidity chamber inside a hybridization oven at 5 r.p.m. for 2 h at 371C. The prehybridization mixture was prepared as follows: 80 ml of Herring Sperm DNA (10 mg/ml, Sigma) and 67.5 ml of human Cot1 DNA (Invitrogen) were precipitated, resuspended in 120 ml of hybridization buffer and denatured for 10 min at 721C. After prehybridization, the prehybridized probe was added onto the slide, and incubated at 5 r.p.m. for 48 h at 371C. Slides were rinsed and washed three times, dried and stored at 41C.
Hybridized slides were scanned using an Axon 4000B scanner (Axon Instruments Inc., Union City, CA, USA) and analysed with the GenePixPro 4.0 image analysis software, where the spots were defined and median fluorescence intensities calculated. The background subtracted fluorescence intensities were imported into a custom-designed Microsoft Excel spreadsheet template. A particular spot was excluded if the duplicate spots have a difference of >10%. The mean values of the duplicate spots were presented in graphical output in the form of the mean log 2 Cy5/Cy3 ratio against distance along each individual chromosome (Mb). Chromosome copy number changes were scored as hemizygous loss if the log 2 ratio was ranging from À0.2 to À0.7, and homozygous deletion if >À0.7, or genomic gain for a log 2 ratio of 0.2-0.5, or amplification if >0.5. Copy number changes seen on the sex chromosomes were excluded in the analysis.
Semiquantitative RT-PCR analysis RT-PCR was performed as previously reported, using GAPDH as a control (Tao et al., 2002) . Primers used were PCDH10F: 5 0 -ACTGCTATCAGGTATGCCTG-3 0 (on exon 1) and PCDH10R: 5 0 -GTCTGTCAACTAGATAGCTG-3 0 (on exon 2). RT-PCR was perfomed for 37 cycles with hot-start, using AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA).
Bisulfite treatment and promoter methylation analysis Bisulfite modification of DNA, MSP and BGS were carried out as described previously (Tao et al., 1999 (Tao et al., , 2002 . The bisulfite-treated DNA was amplified with the methylationspecific primer set, PCDH10bm1: 5 0 -TCGTTAAATA GATACGTTACGC-3 0 , PCDH10bm2: 5 0 -TAAAAACTAA AAACTTTCCGCG-3 0 , or the unmethylation-specific primer set, PCDH10bu1: 5 0 -GTTGTTAAATAGATATGTTATGT-3 0 , PCDH10bu2: 5 0 -CTAAAAACTAAAAACTTTCCACA-3 0 . MSP was perfomed for 40 cycles by using AmpliTaq Gold and hot-start. MSP primers were tested previously for not amplifying any unbisulfited DNA, and the MSP products of several cell lines were confirmed by direct sequencing, indicating that our MSP system is specific. For BGS, bisulfite-treated DNA was amplified using primers, BGS1: 5 0 -GTTGATGTAAATAGGGGAATT-3 0 and BGS2: 5 0 -CTTCAACCTCTAAACCTATAA-3 0 , and the PCR products were cloned into the PCR4-Topo vector (Invitrogen). In all, 8-10 colonies were randomly chosen and sequenced.
Construction of expression plasmids pcDNA3.1( þ )TP53 was constructed by subcloning the fulllength wild-type TP53 from plasmid pC53-SN (gift of Bert Vogelstein) into pcDNA3.1( þ ). pcDNA3.1( þ )PCDH10 was constructed by cloning the PCR product generated from the full-length clone of KIAA1400 (gift from Kazusa DNA Research Institute, Japan) with AccuPrime pfx DNA polymerase (Invitrogen). All the plasmid sequences and orientations were confirmed by sequencing.
Colony formation assays
For colony formation assay using monolayer culture, cells (2 Â 10 5 /well) were plated in a 12-well plate and transfected with expression plasmids or the empty vector (2 mg each), using Lipofectamine 2000 (Invitrogen). Cells were collected and plated in a 10 cm dish 48 h post-transfection, and selected for 16-20 days with G418 (0.4 mg/ml). Surviving colonies (X50 cells/colony) were counted after staining with Giemsa. For colony formation assay using soft agar culture, cells were transfected as above. At 48 h post-transfection, cells were suspended in RPMI 1640 containing 0.35% agar, 10% fetal bovine serum and 0.4 mg/ml G418 and layered on RPMI 1640 containing 0.5% agar, 10% fetal bovine serum and G418 in a six-well plate. Colonies were photographed at day 20 posttransfection. Total RNA from the transfected cells was extracted, treated with DNase I and analysed by RT-PCR to confirm the ectopic expression of PCDH10. All the experiments were performed in triplicate wells three times.
Cell proliferation assay
Stably transfected clones of CNE-1 and EC109 cells expressing PCDH10 were selected as described above. Two clones of each cell line were expanded and used for the assay. Stable clones were seeded in 96-well plates. The colorimetric MTT (Sigma) assay was used to measure cell numbers at various time points. The experiment was performed three times in replicates of six wells.
Wound-healing assay Cell mobility was assessed using a scratch wound assay. Stably transfected cells were cultured in 35 mm dishes until confluent. The cell layers were carefully wounded using sterile tips and washed twice with fresh medium. After incubation for 12, 24, and 36 h, the cells were photographed under a phase-contrast microscope. The experiments were performed in triplicate.
Matrigel invasion assay
The assay was performed using a 24-well invasion chamber consisted of inserts containing 8 mm pore-size PET membrane coated with Matrigel (Becton Dickinson). Cells were harvested from culture flasks by Trypsin/EDTA treatment, washed three times with culture media containing 1% FBS, and resuspended in media containing 1% FBS at a density of 2 Â 10 5 cells/ml. In all, 100 ml of the cell suspension was added into the transwells, with 600 ml of culture media containing 5 mg/ml fibronectin (Sigma) in the lower chamber. After 24 h incubation at 371C, cells that invaded through the Matrigel membrane were stained with Gentian Violet, and counted under a light microscope. The experiment was performed for three times.
Statistical analysis
The results are expressed as values of mean7s.e. Statistical analysis was carried out with Student's t-test, Po0.05 was considered as statistically significant difference.
